Department of Oral Biology, Oral Science Research Center, Department of Applied Life Science, The Graduate School, BK21 Plus Project, Yonsei University College of Dentistry, Seoul, South Korea.
Department of Basic Sciences, Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka.
Front Cell Infect Microbiol. 2018 Jan 15;7:541. doi: 10.3389/fcimb.2017.00541. eCollection 2017.
is associated with hypergastrinemia, which has been linked to the development of gastric diseases. Although the molecular mechanism is not fully understood, is known to modulate the Erk pathway for induction of gastrin expression. Herein we found that an epidermal growth factor (EGF) receptor kinase inhibitor significantly blocked -induced gastrin promoter activity, suggesting involvement of EGF receptor ligands. Indeed, induced mRNA expression of EGF family members such as amphiregulin, EGF, heparin-binding EGF-like growth factor (HB-EGF), and transforming growth factor-α. Of these, specific siRNA targeting of HB-EGF significantly blocked -induced gastrin expression. Moreover, induced HB-EGF ectodomain shedding, which we found to be a critical process for -induced gastrin expression. Thus, we demonstrate a novel role for human mature HB-EGF in stimulating gastrin promoter activity during infection. Further investigation using specific siRNAs targeting each isoform of Raf, Mek, and Erk elucidated that the mechanism underlying -induced gastrin expression can be delineated as the sequential activation of HB-EGF, the EGF receptor, C-Raf, Mek1, and the Erk2 molecules in the MAPK pathway. Surprisingly, whereas Erk2 acts as a potent activator of gastrin expression, siRNA knockdown of Erk1 induced gastrin promoter activity, suggesting that Erk1 typically acts as a repressor of gastrin expression. Elucidation of the mechanism of gastrin modulation by HB-EGF-mediated EGF receptor transactivation should facilitate the development of therapeutic strategies against -related hypergastrinemia and consequently gastric disease development, including gastric cancers.
与高胃泌素血症相关,高胃泌素血症已被证明与胃疾病的发展有关。虽然其分子机制尚未完全阐明,但已知可调节 Erk 通路以诱导胃泌素表达。在此,我们发现表皮生长因子(EGF)受体激酶抑制剂可显著阻断诱导的胃泌素启动子活性,提示 EGF 受体配体的参与。事实上,诱导 EGF 家族成员如 Amphiregulin、EGF、肝素结合 EGF 样生长因子(HB-EGF)和转化生长因子-α的 mRNA 表达。在这些成员中,针对 HB-EGF 的特定 siRNA 显著阻断了诱导的胃泌素表达。此外,诱导 HB-EGF 细胞外结构域脱落,我们发现这是诱导胃泌素表达的关键过程。因此,我们证明了人成熟 HB-EGF 在刺激期间诱导胃泌素启动子活性的新作用感染。使用针对 Raf、Mek 和 Erk 的每种同工型的特异性 siRNA 进行进一步研究,阐明了诱导的胃泌素表达的机制可以描绘为 HB-EGF、EGF 受体、C-Raf、Mek1 和 Erk2 分子在 MAPK 通路中的顺序激活。令人惊讶的是,虽然 Erk2 作为胃泌素表达的有效激活剂,但 Erk1 的 siRNA 敲低诱导胃泌素启动子活性,表明 Erk1 通常作为胃泌素表达的抑制剂。阐明 HB-EGF 介导的 EGF 受体反式激活对胃泌素调节的机制应有助于开发针对相关高胃泌素血症的治疗策略,从而促进胃疾病的发展,包括胃癌。